Last updated: 4 September 2024 at 4:50pm EST

Marc Grasso Net Worth




The estimated Net Worth of Marc Grasso is at least 5.07 百万$ dollars as of 3 September 2024. Marc Grasso owns over 7,297 units of Kura Oncology Inc stock worth over 2,599,111$ and over the last 5 years he sold KURA stock worth over 357,579$. In addition, he makes 2,112,280$ as Chief Financial Officer and Chief Business Officer at Kura Oncology Inc.

Marc Grasso KURA stock SEC Form 4 insiders trading

Marc has made over 11 trades of the Kura Oncology Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 7,297 units of KURA stock worth 35,609$ on 3 September 2024.

The largest trade he's ever made was exercising 10,000 units of Kura Oncology Inc stock on 14 September 2020 worth over 290,000$. On average, Marc trades about 3,998 units every 88 days since 2020. As of 3 September 2024 he still owns at least 130,740 units of Kura Oncology Inc stock.

You can see the complete history of Marc Grasso stock trades at the bottom of the page.





Marc Grasso biography

Dr. Marc Grasso M.D. serves as Chief Financial Officer and Chief Business Officer of the Company. He has served as our Chief Financial Officer and Chief Business Officer since August 2018. Prior to joining us, he served as Managing Director at Stifel Financial Corp., an investment bank and financial services company, from March 2013 to July 2018, where he was responsible for building and managing Stifel’s west coast life sciences and biotechnology investment banking business. From June 2010 to February 2013, Dr. Grasso was Managing Director of Investment Banking in the Global Healthcare Group at UBS Group AG, focused on the biotechnology sector, and from May 2008 to June 2010 he was Managing Director of Investment Banking at Leerink Swann LLC (“Leerink”), a specialist investment bank focused on the healthcare sector, where he was instrumental in the west coast expansion of their franchise. Dr. Grasso joined Leerink from Morgan Stanley, where he served as an Executive Director of Investment Banking in the Global Healthcare Group. Prior to joining Morgan Stanley, he was Vice President of Investment Banking in the Global Healthcare Group of Credit Suisse First Boston. He began his career in investment banking at Deutsche Banc Alex. Brown Inc. Dr. Grasso received his M.D. from The Johns Hopkins University School of Medicine, where he also performed research in molecular oncology. He obtained an A.B. in molecular biology with honors from Princeton University.

What is the salary of Marc Grasso?

As the Chief Financial Officer and Chief Business Officer of Kura Oncology Inc, the total compensation of Marc Grasso at Kura Oncology Inc is 2,112,280$. There are 2 executives at Kura Oncology Inc getting paid more, with Kathleen Ford having the highest compensation of 3,485,030$.



How old is Marc Grasso?

Marc Grasso is 47, he's been the Chief Financial Officer and Chief Business Officer of Kura Oncology Inc since 2019. There are 18 older and 2 younger executives at Kura Oncology Inc. The oldest executive at Kura Oncology Inc is Kathleen Ford, 74, who is the Chief Operating Officer.

What's Marc Grasso's mailing address?

Marc's mailing address filed with the SEC is C/O ALECTOR, INC., 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Kura Oncology Inc

Over the last 6 years, insiders at Kura Oncology Inc have traded over 16,903,587$ worth of Kura Oncology Inc stock and bought 50,000 units worth 575,000$ . The most active insiders traders include Faheem HasnainTroy Edward WilsonMary T Szela. On average, Kura Oncology Inc executives and independent directors trade stock every 63 days with the average trade being worth of 626,260$. The most recent stock trade was executed by Teresa Brophy Bair on 20 May 2024, trading 2,615 units of KURA stock currently worth 57,922$.



What does Kura Oncology Inc do?

at kura oncology, we are committed to realizing the promise of precision medicines for cancer. the genomics revolution is transforming how we treat cancer. we now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. this new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. we are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. our development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias. our goal is to help patients with cancer lead better, longer lives.



What does Kura Oncology Inc's logo look like?

Kura Oncology Inc logo

Complete history of Marc Grasso stock trades at Kura Oncology Inc、Alector

日付
#
会社
インサイダー
取引
取引
株式 1株当たりの株価 合計金額 その後の株式数 ソース
3 Sep 2024 Marc Grasso
最高財務責任者
販売 7,297 4.88$ 35,609$
3 Sep 2024
130,740
3 Jun 2024 Marc Grasso
最高財務責任者
販売 6,920 4.80$ 33,216$
3 Jun 2024
138,037
4 Mar 2024 Marc Grasso
最高財務責任者
販売 5,716 6.92$ 39,555$
4 Mar 2024
144,957
4 Dec 2023 Marc Grasso
最高財務責任者
販売 4,574 5.56$ 25,431$
4 Dec 2023
150,673
5 Sep 2023 Marc Grasso
最高財務責任者
販売 1,114 5.19$ 5,782$
5 Sep 2023
32,247
2 Jun 2023 Marc Grasso
最高財務責任者
販売 1,050 6.90$ 7,245$
2 Jun 2023
33,361
2 Mar 2023 Marc Grasso
最高財務責任者
販売 1,291 8.32$ 10,741$
2 Mar 2023
34,411
14 Sep 2020 Marc Grasso
CFO、CBO
オプション行使 10,000 29.00$ 290,000$
14 Sep 2020
10,000
8 Sep 2020 Marc Grasso
CFO、CBO
オプション行使 10,000 15.47$ 154,700$
8 Sep 2020
10,000
25 Aug 2020 Marc Grasso
CFO、CBO
オプション行使 10,000 15.47$ 154,700$
25 Aug 2020
10,000
7 Aug 2020 Marc Grasso
CFO、CBO
販売 10,000 20.00$ 200,000$
7 Aug 2020
0


Kura Oncology Inc executives and stock owners

Kura Oncology Inc executives and other stock owners filed with the SEC include: